Shares Magazine
4.25p+0.00 (+0.00%)27 Nov 2024, 16:03
Jump to:
Genincode PLC Fundamentals
| Company Name | Genincode PLC | Last Updated | 2024-11-27 |
|---|---|---|---|
| Industry | Diagnostics & Research | Sector | Healthcare |
| Shares in Issue | 176.964 m | Market Cap | £7.52 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.07 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0560 | Debt Equity Ratio | 0.0640 |
| Asset Equity Ratio | 1.6564 | Cash Equity Ratio | 1.0494 |
| Quick Ratio | 2.5461 | Current Ratio | 2.60 |
| Price To Book Value | 2.6724 | ROCE | 0 |
Genincode PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Genincode PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £707,000.00 | £1.00 m | £46,000.00 |
| Intangible Assets | £287,000.00 | £310,000.00 | £193,000.00 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £994,000.00 | £1.31 m | £239,000.00 |
| Stocks | £84,000.00 | £20,000.00 | £14,000.00 |
| Debtors | £509,000.00 | £614,000.00 | £265,000.00 |
| Cash & Equivalents | £2.53 m | £9.75 m | £14.56 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £4.19 m | £11.80 m | £15.21 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £2.50 m | £2.18 m | £831,000.00 |
| Creditors after 1 year | £399,000.00 | £1.72 m | £661,000.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £2.90 m | £3.90 m | £1.49 m |
| Net assets | £1.29 m | £7.90 m | £13.72 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £958,000.00 | £958,000.00 | £958,000.00 |
| Share Premium | £15.55 m | £15.55 m | £15.55 m |
| Profit / Loss | -£7.02 m | -£5.75 m | -£4.14 m |
| Other Equity | £1.29 m | £7.90 m | £13.72 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £1.29 m | £7.90 m | £13.72 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | £0.15 | £0.03 | 0 |
| Debt-to-Equity | £0.17 | £0.04 | 0 |
| Assets / Equity | 1.6564 | 1.6564 | 1.6564 |
| Cash / Equity | 1.0494 | 1.0494 | 1.0494 |
| EPS | -£0.07 | -£0.06 | -£0.07 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£7.51 m | -£3.73 m | -£3.09 m |
| Cashflow before financing | -£7.60 m | -£3.77 m | £12.76 m |
| Increase in Cash | -£7.46 m | -£4.46 m | £12.62 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £2.16 m | £1.43 m | £1.15 m |
| Cost of sales | £1.14 m | £798,000.00 | £561,000.00 |
| Gross Profit | £1.02 m | £632,000.00 | £593,000.00 |
| Operating Profit | -£7.15 m | -£5.90 m | -£4.15 m |
| Pre-Tax profit | -£7.02 m | -£5.75 m | -£4.14 m |
Genincode PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension,and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom. |
| Latest Interim Date | 25 Sep 2024 |
| Latest Fiscal Year End Date | 3 Jun 2024 |
Genincode PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-04-26 | Mr. Paul Andrew Peter Foulger | Executive Director,Chief Financial Officer and Company Secretary |
| 2021-11-29 | Mr. David Eric Evans | Non-Executive Director |
| 2024-04-26 | Mr. Matthew Heaton Walls | Executive Director,Chief Executive Officer |
| 2024-04-26 | Mr. William E. Rhodes III | Non-Executive Director,Chairman |
| 2024-04-26 | Mr. Jordi Puig Gilberte | Executive Director,Founder and Chief Operations Officer |
| 2024-06-03 | Mr. Sergio Olivero Rigau | Non-Executive Director |
| 2024-04-26 | Professor Huon Gray CBE | Non-Executive Director |
| 2024-04-26 | Mr. Felix Wilhelm Frueh | Non-Executive Director |
Genincode PLC Contact Details
| Company Name | GENinCode PLC |
|---|---|
| Address | One St. Peters Square, Manchester, M2 3DE |
| Telephone | +44 1865955847 |
| Website | https://www.genincode.com |
Genincode PLC Advisors
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Direct Line Insurance Group PLC | 220.72 | 39.08 |
| Dr. Martens PLC | 65.21 | 12.82 |
| Ti Fluid Systems PLC | 185.60 | 3.69 |
| Admiral Group PLC | 2,550.00 | 3.49 |
| Jd Sports Fashion PLC | 104.80 | 3.10 |
| Spirax Group PLC | 7,105.00 | 2.97 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Ithaca Energy PLC | 107.80 | -10.32 |
| Energean PLC | 1,055.00 | -3.65 |
| Aviva PLC | 474.30 | -3.07 |
| Ocado Group PLC | 316.20 | -2.71 |
| Rhi Magnesita N.V. | 3,015.00 | -2.27 |
| Imperial Brands PLC | 2,580.00 | -2.09 |